Insider Buying: Burning Rock Biotech (NASDAQ:BNR) Director Acquires 24,760 Shares

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 24,760 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average cost of $8.74 per share, with a total value of $216,402.40. Following the transaction, the director directly owned 17,697,436 shares in the company, valued at $154,675,590.64. This trade represents a 0.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han acquired 24,900 shares of Burning Rock Biotech stock. The stock was bought at an average price of $8.00 per share, with a total value of $199,200.00.
• On Wednesday, June 24th, Yusheng Han purchased 250,000 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han bought 5,990 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han acquired 111,110 shares of Burning Rock Biotech stock. The shares were bought at an average price of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was bought at an average price of $9.25 per share, with a total value of $1,942,500.00.

Burning Rock Biotech Price Performance

BNR stock opened at $8.96 on Thursday. The company has a market capitalization of $94.26 million, a P/E ratio of -10.93 and a beta of 1.33. Burning Rock Biotech Limited Sponsored ADR has a twelve month low of $3.22 and a twelve month high of $41.72. The business has a 50 day simple moving average of $12.79 and a 200-day simple moving average of $20.08. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06.

Burning Rock Biotech (NASDAQ:BNR) last issued its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.The firm had revenue of $15.66 million for the quarter, compared to analysts’ expectations of $19.21 million.

Hedge Funds Weigh In On Burning Rock Biotech

Several institutional investors and hedge funds have recently modified their holdings of BNR. Renaissance Technologies LLC grew its position in shares of Burning Rock Biotech by 13.8% in the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after purchasing an additional 4,290 shares during the period. Prospera Financial Services Inc lifted its position in Burning Rock Biotech by 26.0% during the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after buying an additional 6,430 shares during the period. Marshall Wace LLP purchased a new position in Burning Rock Biotech during the fourth quarter worth about $220,000. Finally, Crcm LP boosted its stake in Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after buying an additional 26,809 shares during the last quarter. Hedge funds and other institutional investors own 30.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.